JPMorgan Chase & Co. Sells 35,923 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

JPMorgan Chase & Co. lessened its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 21.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 127,901 shares of the company’s stock after selling 35,923 shares during the period. JPMorgan Chase & Co.’s holdings in Krystal Biotech were worth $23,282,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the stock. Franklin Resources Inc. boosted its position in Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after buying an additional 62,178 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech during the third quarter valued at $40,000. Teachers Retirement System of The State of Kentucky boosted its holdings in Krystal Biotech by 198.2% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 9,010 shares of the company’s stock valued at $1,640,000 after acquiring an additional 5,989 shares during the last quarter. Geode Capital Management LLC increased its position in Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after purchasing an additional 11,411 shares during the period. Finally, Main Management ETF Advisors LLC acquired a new stake in Krystal Biotech in the third quarter worth about $706,000. Institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on KRYS shares. Chardan Capital restated a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a research report on Wednesday, December 18th. Stifel Nicolaus increased their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Citigroup raised their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech presently has a consensus rating of “Buy” and a consensus target price of $206.67.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $156.67 on Thursday. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of 88.51 and a beta of 0.85. The company’s 50 day simple moving average is $175.38 and its 200 day simple moving average is $183.73. Krystal Biotech, Inc. has a fifty-two week low of $107.50 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. During the same period last year, the firm posted ($0.67) earnings per share. The business’s quarterly revenue was up 879.9% compared to the same quarter last year. As a group, analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).